EJSO

Papers
(The H4-Index of EJSO is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Corrigendum to “Patterns of recurrence after esophagectomy following neoadjuvant immunochemotherapy in patients with thoracic esophageal squamous cell carcinoma”. [Europ J Surg Oncol 51 (2025) 109546]91
OBC: Advert Sciencedirect67
Efficacy of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after gynecological cancer surgery: A systematic review and meta-analysis62
From traditional LAT to stereotactic radiotherapy: Evolving options for metastatic soft tissue sarcoma61
Impact of surgical intervention on overall survival in malignant pleural mesothelioma: A population-based cohort study with propensity score matching58
2024 BASO Annual Conference57
50th Anniversary Presidential Edition – David Rosin50
50th Anniversary Presidential Edition – Graeme Poston50
Establishment a nomogram model for preoperative prediction of the risk of cholangiocarcinoma with microvascular invasion42
Correlation of circulating cell-free DNA and Disease-Free Survival in Liposarcoma – A Prospective Cohort Study42
Prediction and validation of pathologic complete response for locally advanced rectal cancer under neoadjuvant chemoradiotherapy based on a novel predictor using interpretable machine learning41
European Society of Surgical Oncology Young Surgeons (Young ESSO): A path for training excellence, inclusive leadership and research engagement40
Pelvic lymph-node dissections in bladder and prostate cancer surgery and the risk of postoperative venous thromboembolism40
A nomogram based on pretreatment radiomics and dosiomics features for predicting overall survival associated with esophageal squamous cell cancer40
SUPPORTING WOMEN WITH ADHERENCE TO ADJUVANT ENDOCRINE THERAPY – RESULTS FROM THE SWEET FEASIBILITY STUDY39
A prospective study evaluating patient reported outcome measures in patients who have undergone chest wall perforator flaps37
NODE MARKING TECHNIQUES AND TARGETED AXILLARY DISSECTION IN CN1 PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY - ANALYSIS OF INITIAL 500 PARTICIPANTS IN ATNEC TRIAL37
Consultant led triage of new referrals: Protecting the one stop clinic37
Impact of Prognostic Nutritional Index on Neoadjuvant Therapy Outcomes in High-Risk Extremity Soft Tissue Sarcomas: Insights from a Latin American Oncology Center36
Neoadjuvant Rectal Score to predict survival in locally advanced rectal cancer patients who underwent surgery after neoadjuvant Chemoradiotherapy - an ambispective study35
Neoadjuvant Chemotherapy and Targeted Axillary Dissection in Patients with Breast Cancer and High Lymph Node Burden at Diagnosis34
Efficacy of cryoablative local treatment for hormone receptor positive localized T1 invasive ductal carcinoma of the breast and its effects on systemic anti-tumoral immunologic response.34
Standardizing eligibility and patient selection for Pressurized Intraperitoneal Aerosol Chemotherapy: a Delphi consensus statement34
Comparison between glasgow prognostic criteria and o-possum / p-possum physiological indices in patients undergoing gastrectomy for gastric adenocarcinoma34
A comparative study on sentinel node biopsy by icg dye with that of pelvic lymph node dissection in Endometrial carcinoma32
Adherence to guideline recommendations for follow-up in patients with DCIS at a large teaching hospital in the Netherlands32
Axillary and breast siliconomas misguiding breast cancer diagnosis and management – A case report31
Gene and protein expression of inflammatory and tissue remodelling factors in the colon adenocarcinoma microenvironment31
Incidence of surgical infection and risk of surgical site infection following colorectal surgery: A single-centre experience.30
Experience with Minimal Invasive Conversion Surgery after Prolonged Chemotherapy: Two Case Reports30
Comparision and evaluation of chatgpt and gemini as a consultant in oncology30
0.11597895622253